timothy sykes logo
CyPath Lung Diagnostic Tool Spurs bioAffinity Technologies’ Growth Thumbnail
ADD US ONG Google News

CyPath Lung Diagnostic Tool Spurs bioAffinity Technologies’ Growth

BRYCE TUOHEY•UPDATED MAR. 17, 2026, 9:18 AM ET
Reviewed by Tim Sykes Fact-checked by Matt Monaco

BioAffinity Technologies Inc.’s stocks have been trading up by 18.85 percent amid promising market advancements.

Candlestick Chart

Live Update At 09:18:06 EDT: On Tuesday, March 17, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 18.85%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

bioAffinity Technologies Inc.’s latest financial figures paint a picture of a company on the move. For starters, its CyPath Lung diagnostic tool has proven immensely successful, with revenues jumping by 87% compared to the previous year. Yet, while the revenue rise is encouraging, the costs of pushing forward a single core product have continued to mount, with losses hitting approximately $14.9M. Now, as a casual observer, you might wonder why a company seeing such a rise in product volume still deals with staggering losses. The short answer lies in its ambitious growth plans, reduction in unproductive segments, and reliance on future market capital for sustenance.

The firm’s strategy has involved cutting unnecessary pathology services and bolstering its cadre of physicians by a remarkable 67%. These moves come as bioAffinity Technologies simultaneously raises an impressive $16.9M aimed at strengthening its liquidity. A dance in the financial world requires such nimble moves—raising money to fuel expansion while keeping a sharp eye on costs.

However, one must scour the intricacies of financial performance to grasp the entirety of bioAffinity’s undertakings. Looking at the key ratios, the gross margin stands strong at 100%, suggesting its revenue is substantial enough to cover the primary costs. Yet, the downside sees the EBIT margin at negative 216.1%, highlighting operating losses before interest and taxes—a symptom of the harsh operational landscape that start-ups like BIAF sometimes navigate.

Let’s paint a fuller picture. With a revenue per share standing at $2.08 and each share ringing up a valuation of $2667 on average, bioAffinity is not resting on laurels. Its market capitalization reflects anticipation, riding on the hope of more test validations, expanded contracts within the VA and military health systems, and a looming market boom. The average price-to-sales ratio lights positive sentiment—valued at 1.41, this ratio aligns with a rapidly maturing company expected to resonate higher revenue vis-à-vis its market price.

A Path Shaping Market Reactions

The narrative of bioAffinity Technologies takes a compelling turn through its latest strides in innovation and market adaption, evidenced by the real-world impact of its CyPath Lung diagnostic series. Delving into the clinical success stories, one marvels at precision—how a patient-centric lung test managed a high-risk smoker worried by pulmonary nodules by determining the improbability of malignancy and thereby reducing undue anxiety. Overactive indoctrination towards the invasive procedures was halted, ending a saga with a surplus of relieved breaths and market possibilities—a testament to innovation steering public health.

The dawning new era for bioAffinity springs forth through unwavering focus on research and trials. A massive 2,000-patient initiative has been launched, concentrating and expanding on multiple sites to refine lung diagnostic processes. By anchoring this trial within VA medical centers and major military hospitals, bioAffinity strengthens its societal stature and taps into a burgeoning health system with promise.

Move across the state lines, directing gaze towards the Brooke Army Medical Center collaboration, and discover the company’s recent undertaking. By pursuing a validation study on sputum samples, bioAffinity positions its CyPath Lung tool as an agile facilitator. The company lays plans to extend the borderlines of sample collections, proposing a shift from traditional bronchoscopies to less invasive tracheal and bronchial suctioning—thereby broadening clinical applicability extends within reach.

More Breaking News

Conclusion

In the intricate weave of financial storytelling, bioAffinity Technologies stands at an intersection of innovation and operational diligence. It charts a path defined by leaps in medical diagnostics, underpinned by clinical victories tallied alongside growth-oriented financial strategies. With its CyPath Lung noninvasive diagnostic centerstage, bioAffinity attracts attention across central health systems, promising stakeholders potentialities reimagined.

As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.” This trading wisdom resonates with bioAffinity’s approach, emphasizing not only their financial gains but also the strategic management of resources to sustain growth. The narrative declares trajectory—the stock envelops a dynamic journey, ready to stir intrigue and trading curiosity from the medical realm to its fiscal horizon. The story has just begun, woven from success, financial savvy, and visionary technology, etching bioAffinity Technologies as an emergent leader within the diagnostic domain.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading BIAF

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”